| 翁正辉1,2 孙喜太2.胃肠道间质瘤的分子分型及靶向治疗[J].,2011,11(12):2371-2375 |
| 胃肠道间质瘤的分子分型及靶向治疗 |
| Molecular Classification and Targeted Therapy of GastrointestinalStromal Tumors |
| |
| DOI： |
| 中文关键词: 胃肠道间质肿瘤 分子生物学 伊马替尼 舒尼替尼 靶向治疗 |
| 英文关键词: Gastrointestinal stromal tumor Molecular biology Imatinib Sunitinib Targeted therapy |
| 基金项目: |
|
| 摘要点击次数: 535 |
| 全文下载次数: 858 |
| 中文摘要: |
| 胃肠道间质瘤（gastrointestinal stromal tumors，GISTs）是消化道常见的间叶肿瘤，不同于消化道真正的平滑肌瘤、神经源性肿
瘤，其发生主要与Kit 基因和血小板衍生生长因子受体α（platelet-derived growth factor receptor alpha，PDGFRα）基因突变有关。
KIT 靶点的发现使得胃肠道间质瘤治疗进入新治疗模式。伊马替尼与舒尼替尼，均为酪氨酸激酶抑制剂，分别被批准为进展期
GISTs 治疗的第一线及第二线靶向治疗药物。本文就GISTs 的分子生物学分型以及分子靶向药物治疗进展作一概述。 |
| 英文摘要: |
| The gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract,
and was different from leiomyoma, neurogenic tumor, which occurs mainly with the Kit gene and platelet-derived growth factor receptor
alpha gene mutation. Targeting KIT has led to a new treatment paradigm in GISTs. Imatinib and sunitinib, both tyrosine kinase inhibitors
directed to KIT, were approved for first- and second- line treatment of metastatic and unresectable GISTs. In this article,we will review
the molecular classification and targeted drug therapy of GISTs . |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
